Citations

Showing 10 of 108094 citations.

CD138− Plasmablastic Lymphoma: A Multi-institutional Study and Review of the Literature
Choudhuri, Jui , Pan, Zenggang , Yuan, Ji, Wu, Xiaojun , Yuan, Youzhong , Agarwal, Beamon , Liu, J M, Maxwell, Y, Wang, Yanhua , Ji, Yuan , Zheng, Gang , Yuan, Ji , Chen, Mingyi , Zheng, Gang , Chen, Zhao , Shi, Yang

Mayo Clinic

Archives of Pathology & Laboratory Medicine | September 26, 2022 | Volume: 147 | Issue: 6 | Pages: 643-654

10.5858/arpa.2021-0462-oa | PMID 36161544 Get It

Context.— Plasmablastic lymphoma (PBL) is a rare aggressive lymphoma, usually positive for CD138 and frequently occurring in the oral cavity of human immunodeficiency virus (HIV) patients. Up to 10% of cases are negative for CD138 and diagnostically very challenging. Objective.— To investigate the appropriate approach to diagnose CD138− plasmablastic lymphoma and avoid misdiagnosis. Design.— We studied 21 cases of CD138− PBL from multiple large institutes in the United States and 21 cases from the literature. Results.— CD138− PBLs were positive for different B/plasma cell markers at various percentages: MUM1 (94.4%; 34 of 36), OCT2 (70.6%; 12 of 17), immunoglobulin light chains (68.8%; 22 of 32), CD38 (68.4%; 13 of 19), CD79a (34.2%; 13 of 38), and PAX5 (15.6%; 5 of 32), suggesting that MUM1, OCT2, immunoglobulin light chains, and CD38 are useful markers to help establish the lineage. A total of 83% of cases (30 of 36) were extraoral lesions. Extraoral lesions showed much lower Epstein-Barr virus (EBV) infection rates (16 of 30; 53.3%) and had worse prognosis. MYC was positive in 80% (8 of 10) of EBV+ cases and 40% (2 of 5) EBV− cases, indicating the importance of MYC in pathogenesis, especially in EBV+ cases. Conclusions.— Our study emphasizes that CD138− PBLs tend to be extraoral lesions, with much lower EBV infection rates, and diagnostically very challenging. Accurate diagnosis requires a thorough investigation and workup by using appropriate markers.
Management of Periprosthetic Joint Infections After Hemiarthroplasty of the Hip
Bureau, Antoine, Azad, Marisa Ann , Abdelbary, Hesham , Azad, Marisa A, Azad, Marisa , Bourget-Murray, Jonathan , Grammatopoulos, George , Garceau, Simon P.

Mayo Clinic

JBJS Reviews | September 26, 2022 | Volume: 10 | Issue: 9 | Pages: No page available

10.2106/jbjs.rvw.22.00020 | PMID 36155552 Get It

» Periprosthetic joint infection (PJI) following hip hemiarthroplasty (HA) is a devastating complication, incurring immense health-care costs associated with its treatment and placing considerable burden on patients and their families. These patients often require multiple surgical procedures, extended hospitalization, and prolonged antimicrobial therapy. » Notable risk factors include older age, higher American Society of Anesthesiologists (ASA) score, inadequate antibiotic prophylaxis, non-antibiotic-loaded cementation of the femoral implant, longer duration of the surgical procedure, and postoperative drainage and hematoma. » Although the most frequent infecting organisms are gram-positive cocci such as Staphylococcus aureus , there is a higher proportion of patients with gram-negative and polymicrobial infections after hip HA compared with patients who underwent total hip arthroplasty. » Several surgical strategies exist. Regardless of the preferred surgical treatment, successful management of these infections requires a comprehensive surgical debridement focused on eradicating the biofilm followed by appropriate antibiotic therapy. » A multidisciplinary approach led by surgeons familiar with PJI treatment and infectious disease specialists is recommended for all cases of PJI after hip HA to increase the likelihood of treatment success.
Aquablation Treatment for Benign Prostate Hyperplasia: Current Standardized Procedure
Zorn, Kevin C. , Elterman, Dean , González, Ricardo R. , Kriteman, Lewis, Pickens, Ryan B., Mehan, Rahul, Comiter, Craig V. , Rijo, Enrique , Barber, Neil , Humphreys, Mitch, Lerner, Lori B. , Te, Alex E., Kaplan, Steve , Bhojani, Naeem , Chughtai, Bilal , Bach, Thorsten , Misraï, Vincent , Helfand, Brian T. , Te, Alexis E.

Mayo Clinic

Journal of Endourology | September 26, 2022 | Volume: 36 | Issue: 1_suppl | Pages: No page available

10.1089/end.2022.0439 | PMID 36154459 Get It

The following video Atlas summary reviews all technical elements of the standardized setup, robotic execution, aquablation procedure, and hemostasis for efficient rapid benign prostate hyperplasia treatment.
Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
Guaraldi, Federica , Zoli, Matteo , Evangelisti, Stefania , Ambrosi, Francesca , Lloyd, Ricardo V., Asioli, Sofia , Zoli, Matteo , Righi, Alberto , Asioli, Sofia , Morandi, Luca , Mazzatenta, Diego , Righi, Alberto , Tonon, Caterina , Giannini, Caterina

Mayo Clinic

Clinical Endocrinology | September 26, 2022 | Volume: 97 | Issue: 6 | Pages: 763-772

10.1111/cen.14827 | PMID 36161330 Get It

AbstractObjectiveTo profile clinically non‐aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, microRNAs (miRNA)/long noncoding RNA (LncRNA)‐post‐transcriptional regulators and therapy targets.DesignRetrospective observational study.Patients and MeasurementsA total of 64 non‐aggressive and 41 aggressive PAs/PitNETs and 6 pituitary carcinomas treated by endoscopic surgery with ≥1‐year follow‐up were included. Somatic mutations of 17 genes and DNA methylation of 22 genes were assessed. Ten normal pituitaries were used as control.ResultsWe found at least one mutation in 17 tumours, including 6/64 non‐aggressive, 10/41 aggressive PAs/PitNETs, and 1/6 pituitary carcinoma. AIP (N = 6) was the most frequently mutated gene, followed by NOTCH (4), and TP53 (3). Hypermethylation of PARP15, LINC00599, ZAP70 was more common in aggressive than non‐aggressive PAs/PITNETs (p < .05). Lower levels of methylation of AIP, GNAS and PDCD1 were detected in aggressive PAs/PITNETs than non‐aggressive ones (p < .05). For X‐linked genes, males presented higher level of methylation of FLNA, UXT and MAGE family (MAGEA11, MAGEA1, MAGEC2) genes in aggressive vs. non‐aggressive PAs/PITNETs (p < .05).In pituitary carcinomas, methylation of autosomal genes PARP15, LINC00599, MIR193 and ZAP70 was higher than in PAs/PITNETs, while X‐linked genes methylation level was lower.ConclusionsSomatic mutations and methylation levels of genes involved in cell proliferation/differentiation, miRNA/LncRNA‐post‐transcriptional regulators and targets of antineoplastic therapies are different in non‐aggressive and in aggressive PAs/PitNETs. Methylation profile also varies according to gender. Combined genetic‐epigenetic analysis, in association with clinico‐radiological‐pathological data, may be of help in predicting PA/PitNET behaviour.
Understanding sex differences in neurovascular dysfunction with obstructive sleep apnoea: could the proof be in the protons?
Bock, Joshua M. , Dillon, Gabrielle A. , Bock, Joshua , Harvey, Ronée E.

Mayo Clinic

The Journal of Physiology | September 26, 2022 | Volume: 600 | Issue: 21 | Pages: 4547-4548

10.1113/jp283814 | PMID 36156801 Get It

Quality Indicators for Capsule Endoscopy and Deep Enteroscopy
Leighton, Jonathan A. , Brock, Andrew, Semrad, Carol E. , Hass, David J., Guda, Nalini M. , Barkin, Jodie A. , Eisen, Glenn M.

Mayo Clinic

American Journal of Gastroenterology | September 26, 2022 | Volume: 117 | Issue: 11 | Pages: 1780-1796

10.14309/ajg.0000000000001903 | PMID 36155365 Get It

INTRODUCTION: Capsule endoscopy (CE) and deep enteroscopy (DE) can be useful for diagnosing and treating suspected small-bowel disease. Guidelines and detailed recommendations exist for the use of CE/DE, but comprehensive quality indicators are lacking. The goal of this task force was to develop quality indicators for appropriate use of CE/DE by using a modified RAND/UCLA Appropriateness Method. METHODS: An expert panel of 7 gastroenterologists with diverse practice experience was assembled to identify quality indicators. A literature review was conducted to develop a list of proposed quality indicators applicable to preprocedure, intraprocedure, and postprocedure periods. The panelists reviewed the literature; identified and modified proposed quality indicators; rated them on the basis of scientific evidence, validity, and necessity; and determined proposed performance targets. Agreement and consensus with the proposed indicators were verified using the RAND/UCLA Appropriateness Method. RESULTS: The voting procedure to prioritize metrics emphasized selecting measures to improve quality and overall patient care. Panelists rated indicators on the perceived appropriateness and necessity for clinical practice. After voting and discussion, 2 quality indicators ranked as inappropriate or uncertain were excluded. Each quality indicator was categorized by measure type, performance target, and summary of evidence. The task force identified 13 quality indicators for CE and DE. DISCUSSION: Comprehensive quality indicators have not existed for CE or DE. The task force identified quality indicators that can be incorporated into clinical practice. The panel also addressed existing knowledge gaps and posed research questions to better inform future research and quality guidelines for these procedures.
Genetic Architecture of Acute Myocarditis and the Overlap With Inherited Cardiomyopathy
Lota, Amrit , Hazebroek, Mark R. , Theotokis, Pantazis , Salmi, Sara, Halliday, Brian P. , Verdonschot, Job A.J. , Meena, Devendra, Owen, Ruth , Iacob, Alma, Yazdani, Momina , Hammersley, Daniel , Jones, Richard E. , Wage, Riccardo, Buchan, Rachel , Vivian, Fredrik, Hafouda, Yakeen , Noseda, Michela , Gregson, John , Mittal, Tarun , Wong, Joyce , Robertus, Jan Lukas , Baksi, A. John , Vassiliou, Vassilios S. , Pantazis, Antonis, Barton, Paul J.R. , Pennell, Dudley J. , García‐Pavía, Pablo , Ware, James S. , Prasad, Sanjay, Lota, Amrit S , de Marvao, Antonio , Hammersley, Daniel J , Wage, Riccardo , Buchan, Rachel , Vassiliou, Vassilios , Tzoulaki, Ioanna , Barton, Paul J R , Pennell, Dudley J , Garcia-Pavia, Pablo , Cooper, Leslie T , Heymans, Stephane , Ware, James S , Theotokis, Pantazis , Wassall, Rebecca, Tayal, Upasana , Marvao, Antonio de , Cleland, John G.F. , Cook, Stuart A. , Cooper, Leslie T. , Heymans, Stéphane

Mayo Clinic

Circulation | September 26, 2022 | Volume: 146 | Issue: 15 | Pages: 1123-1134

10.1161/circulationaha.121.058457 | PMID 36154167 Get It

Background: Acute myocarditis is an inflammatory condition that may herald the onset of dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM). We investigated the frequency and clinical consequences of DCM and ACM genetic variants in a population-based cohort of patients with acute myocarditis. Methods: This was a population-based cohort of 336 consecutive patients with acute myocarditis enrolled in London and Maastricht. All participants underwent targeted DNA sequencing for well-characterized cardiomyopathy-associated genes with comparison to healthy controls (n=1053) sequenced on the same platform. Case ascertainment in England was assessed against national hospital admission data. The primary outcome was all-cause mortality. Results: Variants that would be considered pathogenic if found in a patient with DCM or ACM were identified in 8% of myocarditis cases compared with <1% of healthy controls ( P =0.0097). In the London cohort (n=230; median age, 33 years; 84% men), patients were representative of national myocarditis admissions (median age, 32 years; 71% men; 66% case ascertainment), and there was enrichment of rare truncating variants (tv) in ACM-associated genes (3.1% of cases versus 0.4% of controls; odds ratio, 8.2; P =0.001). This was driven predominantly by DSP -tv in patients with normal LV ejection fraction and ventricular arrhythmia. In Maastricht (n=106; median age, 54 years; 61% men), there was enrichment of rare truncating variants in DCM-associated genes, particularly TTN -tv, found in 7% (all with left ventricular ejection fraction <50%) compared with 1% in controls (odds ratio, 3.6; P =0.0116). Across both cohorts over a median of 5.0 years (interquartile range, 3.9–7.8 years), all-cause mortality was 5.4%. Two-thirds of deaths were cardiovascular, attributable to worsening heart failure (92%) or sudden cardiac death (8%). The 5-year mortality risk was 3.3% in genotype-negative patients versus 11.1% for genotype-positive patients ( P adjusted =0.08). Conclusions: We identified DCM- or ACM-associated genetic variants in 8% of patients with acute myocarditis. This was dominated by the identification of DSP -tv in those with normal left ventricular ejection fraction and TTN -tv in those with reduced left ventricular ejection fraction. Despite differences between cohorts, these variants have clinical implications for treatment, risk stratification, and family screening. Genetic counseling and testing should be considered in patients with acute myocarditis to help reassure the majority while improving the management of those with an underlying genetic variant.
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT
Jayne, David , Walsh, Michael , Merkel, Peter A. , Peh, Chen Au , Szpirt, Wladimir , Puéchal, Xavier , Fujimoto, Shouichi , Hawley, Carmel M. , Khalidi, Nader , Jones, Rachel , Gregorini, Gina , Harper, Lorraine , Clark, William F. , Smyth, Lucy , Ito‐Ihara, Toshiko , Brezina, Biljana , Mazzetti, Andrea , McAlear, Carol A. , Reidlinger, Donna , Mehta, Samir , Ives, Natalie , Brettell, Elizabeth , Jarrett, Hugh , Wheatley, Keith , Broadhurst, Elizabeth , Casian, Alina , Pusey, Charles D. , Hawley, Carmel , Flossmann, Oliver , Wald, Ron , Girard, Louis , Levin, Adeera , Gregorini, Gina , Harper, Lorraine , Clark, William , Pagnoux, Christian , Specks, Ulrich , Smyth, Lucy , Ito-Ihara, Toshiko , de Zoysa, Janak , Brezina, Biljana , Mazzetti, Andrea , McAlear, Carol A , Reidlinger, Donna , Mehta, Samir , Ives, Natalie , Brettell, Elizabeth A , Jarrett, Hugh , Wheatley, Keith , Broadhurst, Elizabeth , Casian, Alina , Pusey, Charles D , Merkel, Peter A , Khalidi, Nader A , Jayne, David , Pagnoux, Christian , Specks, Ulrich

Mayo Clinic

Health Technology Assessment | September 26, 2022 | Volume: 26 | Issue: 38 | Pages: 1-60

10.3310/pnxb5040 | PMID 36155131 Get It

Background Anti-neutrophil cytoplasm antibody-associated vasculitis is a multisystem, autoimmune disease that causes organ failure and death. Physical removal of pathogenic autoantibodies by plasma exchange is recommended for severe presentations, along with high-dose glucocorticoids, but glucocorticoid toxicity contributes to morbidity and mortality. The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes. Objectives We aimed to determine the clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis. We also aimed to determine whether or not a reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen with respect to death and end-stage renal disease. Design This was an international, multicentre, open-label, randomised controlled trial. Patients were randomised in a two-by-two factorial design to receive either adjunctive plasma exchange or no plasma exchange, and either a reduced or a standard glucocorticoid dosing regimen. All patients received immunosuppressive induction therapy with cyclophosphamide or rituximab. Setting Ninety-five hospitals in Europe, North America, Australia/New Zealand and Japan participated. Participants Participants were aged ≥ 16 years with a diagnosis of granulomatosis with polyangiitis or microscopic polyangiitis, and either proteinase 3 anti-neutrophil cytoplasm antibody or myeloperoxidase anti-neutrophil cytoplasm antibody positivity, and a glomerular filtration rate of < 50 ml/minute/1.73 m2 or diffuse alveolar haemorrhage attributable to active anti-neutrophil cytoplasm antibody-associated vasculitis. Interventions Participants received seven sessions of plasma exchange within 14 days or no plasma exchange. Oral glucocorticoids commenced with prednisolone 1 mg/kg/day and were reduced over different lengths of time to 5 mg/kg/day, such that cumulative oral glucocorticoid exposure in the first 6 months was 50% lower in patients allocated to the reduced-dose regimen than in those allocated to the standard-dose regimen. All patients received the same glucocorticoid dosing from 6 to 12 months. Subsequent dosing was at the discretion of the treating physician. Primary outcome The primary outcome was a composite of all-cause mortality and end-stage renal disease at a common close-out when the last patient had completed 10 months in the trial. Results The study recruited 704 patients from June 2010 to September 2016. Ninety-nine patients died and 138 developed end-stage renal disease, with the primary end point occurring in 209 out of 704 (29.7%) patients: 100 out of 352 (28%) in the plasma exchange group and 109 out of 352 (31%) in the no plasma exchange group (adjusted hazard ratio 0.86, 95% confidence interval 0.65 to 1.13; p = 0.3). In the per-protocol analysis for the non-inferiority glucocorticoid comparison, the primary end point occurred in 92 out of 330 (28%) patients in the reduced-dose group and 83 out of 325 (26%) patients in the standard-dose group (partial-adjusted risk difference 0.023, 95% confidence interval 0.034 to 0.08; p = 0.5), thus meeting our non-inferiority hypothesis. Serious infections in the first year occurred in 96 out of 353 (27%) patients in the reduced-dose group and in 116 out of 351 (33%) patients in the standard-dose group. The rate of serious infections at 1 year was lower in the reduced-dose group than in the standard-dose group (incidence rate ratio 0.69, 95% confidence interval 0.52 to 0.93; p = 0.016). Conclusions Plasma exchange did not prolong the time to death and/or end-stage renal disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis with severe renal or pulmonary involvement. A reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen and was associated with fewer serious infections. Future work A meta-analysis examining the effects of plasma exchange on kidney outcomes in anti-neutrophil cytoplasm antibody-associated vasculitis is planned. A health-economic analysis of data collected in this study to examine the impact of both plasma exchange and reduced glucocorticoid dosing is planned to address the utility of plasma exchange for reducing early end-stage renal disease rates. Blood and tissue samples collected in the study will be examined to identify predictors of response to plasma exchange in anti-neutrophil cytoplasm in antibody-associated vasculitis. The benefits associated with reduced glucocorticoid dosing will inform future studies of newer therapies to permit further reduction in glucocorticoid exposure. Data from this study will contribute to updated management recommendations for anti-neutrophil cytoplasm antibody-associated vasculitis. Limitations This study had an open-label design which may have permitted observer bias; however, the nature of the end points, end-stage renal disease and death, would have minimised this risk. Despite being, to our knowledge, the largest ever trial in anti-neutrophil cytoplasm antibody-associated vasculitis, there was an insufficient sample size to assess clinically useful benefits on the separate components of the primary end-point: end-stage renal disease and death. Use of a fixed-dose plasma exchange regimen determined by consensus rather than data-driven dose ranging meant that some patients may have been underdosed, thus reducing the therapeutic impact. In particular, no biomarkers have been identified to help determine dosing in a particular patient, although this is one of the goals of the biomarker plan of this study. Trial registration This trial is registered as ISRCTN07757494, EudraCT 2009-013220-24 and Clinicaltrials.gov NCT00987389. Funding This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 38. See the NIHR Journals Library website for further project information.
Cumulative rehospitalizations and implications for subsequent mortality after first-ever ischemic stroke
Yousufuddin, Mohammed , Arumaithurai, Kogulavadanan , Thapa, Prabin , Murad, M. Hassan , Murad, M Hassan

Mayo Clinic

Hospital Practice | September 26, 2022 | Volume: 50 | Issue: 5 | Pages: 393-399

10.1080/21548331.2022.2128575 | PMID 36154554 Get It